Choose Your Country or Region

PD98059

Name: PD98059
Brand: Selleck Chemicals
SKU: S1177
Rating: 5 (423 reviews)

Catalog No.S1177

For research use only.

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR) and functions as an AHR antagonist.

CAS No. 167869-21-8

Selleck's PD98059 has been cited by 423 publications

Purity & Quality Control

Choose Selective MEK Inhibitors

Related Compound Libraries

Other MEK Products

Cobimetinib (GDC-0973)^New

Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM, showing more than 100-fold selectively for MEK1 over MEK2 and showed no significant inhibition when tested against a panel of more than 100 of serine-threonine and tyrosine kinases. Cobimetinib induces apoptosis. Phase 3.
BI-847325^New

BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.
GDC-0623^New

GDC-0623 (G-868) is a potent and ATP-uncompetitive MEK1 inhibitor with K_i of 0.13 nM. Phase 1.
Trametinib (GSK1120212)

Trametinib (GSK1120212, JTP-74057, Mekinist) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2. Trametinib activates autophagy and induces apoptosis.
Mirdametinib (PD0325901)

Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.
Selumetinib (AZD6244)

Selumetinib (AZD6244, ARRY-142886) is a potent, highly selective MEK inhibitor with IC50 of 14 nM for MEK1 and Kd value of 530 nM for MEK2. It also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Selumetinib suppresses cell proliferation, migration and trigger apoptosis. Phase 3.
U0126-EtOH

U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM in cell-free assays, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059. U0126 inhibits autophagy and mitophagy with antiviral activity.
PD184352 (CI-1040)

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. PD184352 (CI-1040) selectively induces apoptosis. Phase 2.
Binimetinib (MEK162)

Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Binimetinib induces G1 cell cycle arrest and apoptosis in human NSCLC cell lines and induces autophagy. Phase 3.
Refametinib (RDEA119)

Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.

Download Inhibitor Catalog

MEK Signaling Pathway Map

Biological Activity

Description

Features

Does not inhibit c-Raf phosphorylated MEK1.

Targets

AhR ^[1] (Cell-free assay)	MEK1 ^[1] (Cell-free assay)
1 μM	2 μM

In vitro

PD98059 inhibits either basal MEK1 or a partially activated MEK produced by mutation of serine at residues 218 and 222 to glutamate (MEK-2E) with IC50 of 2 μM. PD98059 does not inhibit the MAPK homologues JNK and P38. PD98059 is highly selective against MEK, as it does not inhibit a number of other kinase activities including Raf kinase, cAMP-dependent kinase, protein kinase C, v-Src, epidermal growth factor (EGF) receptor kinase, insulin receptor kinase, PDGF receptor kinase, and phosphatidylinositol 3-kinase. PD98059 inhibits PDGF-stimulated activation of MAPK and thymidine incorporation into 3T3 cells with IC50 of ~10 μM and ~7 μM, respectively. ^[1] PD98059 potently prevents the activation of MEK1 by Raf or MEK kinase with IC50 of 4 μM, and weakly inhibits the activation of MEK2 by Raf with IC50 of 50 μM. PD98059 does not inhibit the activation of MEK homologues MKK4 and RK kinase that participate in stress and interleukin-1-stimulated kinase cascades in KB and PC12 cells, and the activation of p70 S6 kinase by insulin or epidermal growth factor in Swiss 3T3 cells. ^[2] PD98059 completely blocks the nerve growth factor (NGF)-induced differentiation of PC12 cells without altering cell viability. ^[3] PD98059 inhibits the proliferation of RAW264.7 cells in the culture containing RANKL in a dose-dependent manner, resulting in an apparent decrease of TRAP-positive cells. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

A2780	MUHGeY5kfGmxbjDBd5NigQ>?	NHvsN5AzOMLizszN	MnrmNUBp		NHPVSVZjdG:la4OgSHRETC2rbnT1Z4VlKESUNTDlfJBz\XO\|aX;u	NEDNOVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[5Olg3Oid-MkO2PVY5PjJ:L3G+
AML 1#	MojTRZBweHSxc3nzJGF{e2G7	MW[yNOKh\|ryP	NY[5b2ZjOTJiaB?=		NIWxe4NmdmijbnPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JHMy	M3fveVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{C2OlkyLz5{M{ewOlY6OTxxYU6=
KG-1	NYi3WpZ7SXCxcITvd4l{KEG\|c3H5	NIDZW2IzOMLizszN	MV2xNkBp		NFvVN21mdmijbnPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JHMy	M2fCRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{C2OlkyLz5{M{ewOlY6OTxxYU6=
HUVECs	M1PyU2Fxd3C2b4Ppd{BCe3OjeR?=	Mn;oNk81KM7:TR?=	M1S2PFI1NzR6IHi=		NYPSepUzcW6mdXPld{Bk\WyuIHTlZZRp	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzdyN{WyNEc,OjN5MEe1NlA9N2F-
HepG2	MVzGeY5kfGmxbjDBd5NigQ>?	NWe0PIU{OjEEoN88US=>	MUCyOEBp		M{Dy[YlvcGmkaYTzJJRp\SCKTz2xJJBzd3SnaX6g[ZhxemW\|c3nvckBkdy22cnXheIVlKHerdHigcYV1\m:{bXnu	Mm[3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5MEe2NFkoRjJ\|N{C3OlA6RC:jPh?=
NB4	NX3jOlFISXCxcITvd4l{KEG\|c3H5	MmXxNVAwOjBxNkCg{txO	M2\wOlEvPSCq	NXm3dI1yTE2VTx?=	MkXE[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHPvMZRz\WG2ZXSge4l1cCCSYXPsbZRigGWu	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd\|NUW0NUc,OjN5M{W1OFE9N2F-
BxPC-3 cells	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXyxOYIyOjEEoN88US=>	NWPGeXhWOC53IHi=		NWCydHVKcW6qaXLpeJMhXkWJRj3BMZJm\3WuYYTl[EBJXV[HQzDndo94fGhiYX7kJJR2[mViZn;ycYF1cW:wIHnu[JVk\WRiYomgVGFTNTJiQWC=	MkPHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5NkSwOFYoRjJ\|N{[0NFQ3RC:jPh?=
MKN45	MmrhRZBweHSxc3nzJGF{e2G7	NFjJNHQyOCEQvF5CpC=>	NGX1T2ozPCCq		M{i3T4lv[3KnYYPld{B1cGViRFHQWE1qdmS3Y3XkJINmdGxiYYDvdJRwe2m\|	NEXQcZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e5NlU5QCd-MkO3PVI2QDh:L3G+
SGC7901	MYDBdI9xfG:\|aYOgRZN{[Xl?	NGfOXGEyOCEQvF5CpC=>	NILZR3czPCCq		NHzUZmtqdmO{ZXHz[ZMhfGinIFTBVHQucW6mdXPl[EBk\WyuIHHwc5B1d3Orcx?=	M{W3V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{myOVg5Lz5{M{e5NlU5QDxxYU6=
MKN45	NUjwSWhmTnWwY4Tpc44hSXO\|YYm=	M163WFExKM7:TdMg	MYGyOEBp		MU\pcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDwbI9{eGixconsZZRm\CCHUluxM\|I>	NI\kN2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e5NlU5QCd-MkO3PVI2QDh:L3G+
SGC7901	M375OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLmN4wyOTBizszNxsA>	M4DLVVI1NzR6L{eyJIg>		M3rGXYlvcGmkaYTzJINmdGxiZ4Lve5RpKGOxLYTy[YF1\WRid3n0bEBFSVCW	MlG4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OUK1PFgoRjJ\|N{myOVg5RC:jPh?=
MKN45	NXjvZ29jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUWxNEDPxE4EoB?=	M4PaSlI1NzR6L{eyJIg>		Mn3CbY5pcWKrdIOgZ4VtdCCpcn;3eIgh[29vdILlZZRm\CC5aYToJGRCWFR?	NIDsRpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e5NlU5QCd-MkO3PVI2QDh:L3G+
SGC7901	NFfzWotHfW6ldHnvckBCe3OjeR?=	M{TKOlExKM7:TdMg	MkflNlQhcA>?		MknHbY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[gdIhwe3Cqb4L5cIF1\WRiRWLLNU8z	M1PDNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{myOVg5Lz5{M{e5NlU5QDxxYU6=
HUASMCs	M2nnfWZ2dmO2aX;uJGF{e2G7	Mm[zNVAh\|ryPwrC=	NHX4ZXkzPCCq		NELHW5plcW2rbnnzbIV{KEGwZzDJTU1k[XW\|ZXSgV29EWzNibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:wwrC=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzhzNkS2PEc,OjN6MU[0Olg9N2F-
HUASMCs	M{H1bmZ2dmO2aX;uJGF{e2G7	Mm\ENVAh\|ryPwrC=	NV7DbGlQOjRiaB?=		NXOxb4xbcW6qaXLpeJMhSW6pIFnJMYlv\HWlZXSgSXJMOS9{IIDoc5NxcG:{eXzheIlwdiCuZY\lcC=>	NYHSVZB{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4NVY1PjhpPkKzPFE3PDZ6PD;hQi=>
EPOR/CR3	M{LyT2Z2dmO2aX;uJGF{e2G7	M{LYVFUxyqEQvF2=	M{XET\|MhcA>?		NUL6SZdZemWmdXPld{BGWE9iYX7kM49zKEmOLUOtbY5lfWOnZDD0bIUhfHm{b4PpcoUheGixc4Doc5J6dGG2aX;uxsA>	Mlr3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6MkC3N\|EoRjJ\|OEKwO\|MyRC:jPh?=
NB4	M1mzT2Z2dmO2aX;uJGF{e2G7	MYWxNEDPxE4EoB?=	MU[3NkBp	NYHCNldSTE2VTx?=	NHTh[llqdmirYnn0d{Bl[XOjdHnubYIucW6mdXPl[EBETDFzYjDlfJBz\XO\|aX;u	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh{NUW4OUc,OjN6MkW1PFU9N2F-
HL60	NFXYN5NHfW6ldHnvckBCe3OjeR?=	NGPVTmMzOMLizszN	NH3oSpI4OiCq	M4nTSGROW09?	M4n4SolvcGmkaYTzJIRie2G2aX7pZk1qdmS3Y3XkJGNFOTGkIHX4dJJme3Orb36=	M124fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEK1OVg2Lz5{M{iyOVU5PTxxYU6=
HUVECs	Mk\oSpVv[3Srb36gRZN{[Xl?	MYSyOUDPxE1?	NIDFXFAyKGh?		MVrpcoNz\WG\|ZTDOSk3PwkJicE[1JI52[2ynYYKgeJJidnOub3PheIlwdg>?	MljFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MEGwNFgoRjJ\|OUCxNFA5RC:jPh?=
LNCaP	MV;GeY5kfGmxbjDBd5NigQ>?	NXWxN\|g2OTBizszNxsA>	MkGzNUBp		NEn3dYtl\WO{ZXHz[ZMhfGinIFXHSkB2eHKnZ4XsZZRm\CCyLWnCMVE>	MnHwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6M{izNVgoRjJ\|OEO4N\|E5RC:jPh?=
HL-60	NUP6[VNVSXCxcITvd4l{KEG\|c3H5	NXTGXHBwPTEEoN88US=>	M3q5dVEhcA>?		MX;y[ZNkfWW\|IFLBNVQ2KG2nZHnheIVlKGGyb4D0c5Nqew>?	NX;LeoNmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OFg4PTFpPkKzPVQ5PzVzPD;hQi=>
HepG2	NIT5[YdHfW6ldHnvckBCe3OjeR?=	M3PXWFQxKM7:TR?=	MUi2M\|EzKGh?		MV;pcohq[mm2czD0bIUhcW6lcnXhd4Uhd2ZicD3FVmsyKGGwZDDwMYMuUnWwIIDyc5RmcW5iZYjwdoV{e2mxbjDifUBRVA>?	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl2Mki1NUc,OjN7NEK4OVE9N2F-
HPAF-II	NWC0dpNyTnWwY4Tpc44hSXO\|YYm=	MkHCNVAh\|ryPwrC=	MXm2JIg>		MWLpcoNz\WG\|ZTDtbXIuOTR\|IHX4dJJme3Orb36=	Mmm0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7N{O3NVAoRjJ\|OUezO\|ExRC:jPh?=
BxPC-3	MonMSpVv[3Srb36gRZN{[Xl?	MmX0NVAh\|ryPwrC=	MoW0OkBp		M{eyR4lv[3KnYYPlJI1qWi1zNEOg[ZhxemW\|c3nvci=>	NELuXmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m3N\|cyOCd-MkO5O\|M4OTB:L3G+
COLO205	NGS0OmpCeG:ydH;zbZMhSXO\|YYm=	NIHxb\|EyOC9{MD:0NEDPxE1?	NETmV2QzPCCq		MXjpcoR2[2W\|IFTORUBt[WSmZYKg[o9zdWG2aX;u	MljpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMUmxNFgoRjJ2MEG5NVA5RC:jPh?=
G292	Ml\hRZBweHSxc3nzJGF{e2G7	NVTsfndpOzEEoN88US=>	MX:yJIg>		NGHFWVdz\XO2b4Lld{Bk[XC\|YXnjbY4ucW6mdXPl[EBk\WyuIHTlZZRp	MnHNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMUK5N\|AoRjJ2MEGyPVMxRC:jPh?=
SGC7901	M4\sWmFxd3C2b4Ppd{BCe3OjeR?=	MVqyNOKh\|ryP	MXyxJIg>		MXjpcohq[mm2czDhdI9xfG:\|aYOgbY5lfWOnZDDifUBKTk5vzsJCpIFv\CB34pEyMWRHXVJ?	MnXyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMke3OVAoRjJ2MEK3O\|UxRC:jPh?=
MGC803	NV\mXWRiSXCxcITvd4l{KEG\|c3H5	NE\oToozOMLizszN	NYn6RWxGOSCq		M4n6WIlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEmITj5OteKh[W6mIEZihNIuTE[XUh?=	MmPmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMke3OVAoRjJ2MEK3O\|UxRC:jPh?=
HPMC	NEi3[XNCeG:ydH;zbZMhSXO\|YYm=	MXyxNOKh\|ryP	M1v3SFI1yqCq		Ml;wdoV3\XK\|ZYOg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY5lfWOnZDDifUBJT1CGUx?=	M4S3RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MESyPFM5Lz5{NEC0Nlg{QDxxYU6=
HCT-8	NIjsWppCeG:ydH;zbZMhSXO\|YYm=	MoHVNVDDqM7:TR?=	MmrENlTDqGh?		NXHYU3kx\GWlcnXhd4V{KGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkhPS2IVR?=	NEe2VoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5OVg3Oyd-MkSwPVU5PjN:L3G+
HPMC	NXLCWnNrTnWwY4Tpc44hSXO\|YYm=	M1XQfFExyqEQvF2=	MVO0PEBp		Mn7sdoV3\XK\|ZYOgeIhmKGOqYX7n[ZMhcW5iY3XscEBud3KyaH;sc4d6KGmwZIXj[YQh[nliSFfQSHM>	M1HxSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MESyPFM5Lz5{NEC0Nlg{QDxxYU6=
A549	NFHBfplHfW6ldHnvckBCe3OjeR?=	MlnDOVDDqM7:TR?=	M3jFTVIhcA>?		NWqx[XNx[myxY3vzJGVTUyCyaH;zdIhwenmuYYTpc44hdWWmaXH0[YQh[nliMTyyMW5S	NIjL[lE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC2O\|czPyd-MkSwOlc4Ojd:L3G+
Caco-2	NUjrdo1CSXCxcITvd4l{KEG\|c3H5	NEjOPFkyOMLizszN	MVeyOOKhcA>?		M2q1eYRm[3KnYYPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JFUuTlV?	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7NUi2N{c,OjRyOUW4OlM9N2F-
AGS	Mlf2SpVv[3Srb36gRZN{[Xl?	NI\5V2QyOCEQvF5CpC=>	M2DVSlAvPSCq		MorlbY5pcWKrdIOgeIhmKHWycnXneYxifGmxbjDv[kB1cGViSVytPEBo\W6n	M2n2VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUC2NVY3Lz5{NEGwOlE3PjxxYU6=
Ca9-22	MXzGeY5kfGmxbjDBd5NigQ>?	MofxN{DPxE1?	M2r2flEwOiCq		M{fIPJJm\HWlZYOgTIJTNWmwZIXj[YQhSVSILUKgdIhwe3Cqb4L5cIF1cW:w	Mk\CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMk[1N\|IoRjJ2MUK2OVMzRC:jPh?=
Ca9-22	M3PFWWZ2dmO2aX;uJGF{e2G7	NGi3O5U{KM7:TR?=	MkjBNUBp		MWDhZo9tcXOqZYOgeIhmKGGkaXzpeJkhd2ZiSHLSJJRwKGmwZIXj[UBKVC16IIDyc4R2[3Srb36=	NFTBNZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGyOlU{Oid-MkSxNlY2OzJ:L3G+
HAECs	M4f5XWZ2dmO2aX;uJGF{e2G7	MVyxNEDPxE1?	Mkj0NUBp		NX;IeFFiyqCjdITlcpVifGW\|IGTOSk3PuS2\|dHnteYxifGWmIFnDRW0uOSCjbnSgWmNCVS1zIHX4dJJme3Orb36=	NX\Tfo1KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxN\|Q3PTdpPkK0NVM1PjV5PD;hQi=>
Caco-2	M{DPWmZ2dmO2aX;uJGF{e2G7	MVe1NOKh\|ryP	M{LGNFQ5cA>?	NXjm[oE3TE2VTx?=	NUTSd4Zn\W6qYX7j[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCVQ17ONWEtTli\REOsxsBNS1RuwrDMU3gtyqCKSV[zRUzDqFqJMU[sxsBRTEV4QdMgZY5lyqCOR1HMV\|E3yqCpZX7ld:Kh[29vdILlZZRm\CC5aYToJGRmgA>?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF4MU[5OUc,OjRzNkG2PVU9N2F-
MCF-7	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PjTFExKM7:TR?=	NFHERoY1QGh?	MVLEUXNQ	NV;NUJlZemW4ZYLz[ZMhSk6ILXnu[JVk\WRiY3XscEBkgWOuZTDhdpJme3R?	M4fwfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MU[zOFA1Lz5{NEG2N\|QxPDxxYU6=
SMMC7721	NFfLTZZHfW6ldHnvckBCe3OjeR?=	M4DxWFI2NzVyIN88US=>	M3zhflI1KGh?		NV3KT3l6e3WycILld5NmeyC2aHWg[ZhxemW\|c3nvckBw\iCyLVHreEBweiCyLVXST\|EwOsLi	M1;4ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MU[4NFU3Lz5{NEG2PFA2PjxxYU6=
SGC7901	M{fqNGFxd3C2b4Ppd{BCe3OjeR?=	MkC2OVDDqM7:TR?=	M13PSlI1NzR6L{eyJIg>	NFjXZYpFVVOR	MnvlbY5lfWOnczDhdI9xfG:\|aYOgZ49u[mmwZXSge4l1cCCMQVuyJJNpWk6D	NEnYdpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG3PFI1OCd-MkSxO\|gzPDB:L3G+
7721	MXPBdI9xfG:\|aYOgRZN{[Xl?	Mn72N\|Ah\|ryP	NYDsSmhnPSCm		MUfk[YNz\WG\|ZYOgZ4VtdCCycn;sbYZmemG2aX;u	MlTnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{MUGyOVMoRjJ2MkGxNlU{RC:jPh?=
DLD-1	M1;tVGZ2dmO2aX;uJGF{e2G7	NITxN\|UzOMLizszN	NVHEfHZFPDhiaB?=		NWfhUW43emWmdXPld{B1cGViQl7JVFMh\XiycnXzd4lwdiCycnWteJJm[XSnZDD3bZRpKDVvYYrhMYRE	Mlq1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{MUG1PFEoRjJ2MkGxOVgyRC:jPh?=
HT-29	MX;GeY5kfGmxbjDBd5NigQ>?	MWGyNOKh\|ryP	NUXZeZJZPDhiaB?=		MnWydoVlfWOnczD0bIUhSk6LUEOg[ZhxemW\|c3nvckBxemVvdILlZZRm\CC5aYToJFUu[XqjLXTD	NYTBSmp4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyNVE2QDFpPkK0NlEyPThzPD;hQi=>
7402	NV\Ge\|RPSXCxcITvd4l{KEG\|c3H5	Mn;KN\|Ah\|ryP	NXX1O2VHPSCm		NYq0eVNY\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdg>?	NUnPbYVDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyNVEzPTNpPkK0NlEyOjV\|PD;hQi=>
MCF-7	MWPGeY5kfGmxbjDBd5NigQ>?	NFK0PGkzOCEQvF2=	MXmxJIg>		NW\HU5VH[WKxbHnzbIV{KGW6cILld5Nqd25ib3[gdIhwe3Cqb4L5cIF1\WRiRWLLJINwNXS{ZXH0cYVvfCC5aYToJINwdmq3Z3H0[S=>	NF7KUXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKxOlI5QSd-MkSyNVYzQDl:L3G+
MCF-7	Ml[3RZBweHSxc3nzJGF{e2G7	MXWyNEDPxE1?	M3\PW\|EhcA>?		NXO4V4h2cW6lcnXhd4V{KGOjc4Dhd4UuQSCnbor5cYUh[WO2aY\peJk>	MnPHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{MU[yPFkoRjJ2MkG2Nlg6RC:jPh?=
CRL-2302	NVzNW\|c3TnWwY4Tpc44hSXO\|YYm=	MXSyNEDPxE1?	NVLWcHdlOC53IHi=		NWfkRlJbcW6qaXLpeJMhSXCnbHnuMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJGVzcyCjbnSgRYt1	NYXJVpFKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyNlc6OThpPkK0NlI4QTF6PD;hQi=>
ARPE-19	MnTISpVv[3Srb36gRZN{[Xl?	NFXpc5czOCEQvF2=	NVXpNYFDOC53IHi=		MlPWbY5pcWKrdIOgRZBmdGmwLXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIFXyb{BidmRiQXv0	NX7QN4kxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyNlc6OThpPkK0NlI4QTF6PD;hQi=>
MG-63	MYjGeY5kfGmxbjDBd5NigQ>?	MlzQNlAh\|ryP	NFPRTnIxNjViaB?=		MmPoZoxw[2u\|IITo[UBEUC2rbnT1Z4VlKHCqb4PwbI9zgWyjdHXkJGVNUzFicILveIVqdiCneIDy[ZN{cW:w	NIrXWZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKzPVY1OCd-MkSyN\|k3PDB:L3G+
SGC-7901	NHjTUXpCeG:ydH;zbZMhSXO\|YYm=	NHfXNZgzOCEQvF2=	Ml33NlQhcA>?		MnvabY5pcWKrdIOgR3AudWWmaXH0[YQh[XCxcITvd4l{	M4HzSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkSxN\|UyLz5{NEK0NVM2OTxxYU6=
NUGC2	NXPqbHQ1TnWwY4Tpc44hSXO\|YYm=	MWS1NEDPxE1?	MkfZOFghcA>?	NGLCWpBFVVOR	NHTqVYtqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDIUGEuSTB{IH;yJGhNSS2DMkSgcY9t\WO3bHXz	NVu4So1ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQxOjNpPkK0NlQ1ODJ\|PD;hQi=>
NUGC3	MWTGeY5kfGmxbjDBd5NigQ>?	NGjSWZg2OCEQvF2=	NX;odYM3PDhiaB?=	MX;EUXNQ	NE[1PYZqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDIUGEuSTB{IH;yJGhNSS2DMkSgcY9t\WO3bHXz	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2NECyN{c,OjR{NESwNlM9N2F-
KATOIII	NEDkbmRHfW6ldHnvckBCe3OjeR?=	MYO1NEDPxE1?	MXq0PEBp	Mmj3SG1UVw>?	NVrnS3R3cW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=>	Mny2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NESwNlMoRjJ2MkS0NFI{RC:jPh?=
NCI-N87	NFLDS4hHfW6ldHnvckBCe3OjeR?=	NXK1bWdlPTBizszN	MUK0PEBp	NUTa[49PTE2VTx?=	MVjpcoNz\WG\|ZYOg[ZhxemW\|c3nvckBw\iCKTFGtRVAzKG:{IFjMRU1COjRibX;s[YN2dGW\|	MnvkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NESwNlMoRjJ2MkS0NFI{RC:jPh?=
OE19	Mn:xSpVv[3Srb36gRZN{[Xl?	MXu1NEDPxE1?	MknDOFghcA>?	Ml70SG1UVw>?	MWLpcoNz\WG\|ZYOg[ZhxemW\|c3nvckBw\iCKTFGtRVAzKG:{IFjMRU1COjRibX;s[YN2dGW\|	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2NECyN{c,OjR{NESwNlM9N2F-
MKN7	M1GzdmZ2dmO2aX;uJGF{e2G7	MV61NEDPxE1?	NFOwcHk1QCCq	M{XRTmROW09?	NWDzemo5cW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=>	NFvPcIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0OFAzOyd-MkSyOFQxOjN:L3G+
TE4	NX\afYlpTnWwY4Tpc44hSXO\|YYm=	M4rF[\|UxKM7:TR?=	NU\5OFJ4PDhiaB?=	M3rRZmROW09?	M1uyOJVxemWpdXzheIV{KHSqZTDlfJBz\XO\|aX;uJI9nKEiOQTDjcIF{eyCL	NFT3OYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0OFAzOyd-MkSyOFQxOjN:L3G+
KYSE30	MlmxSpVv[3Srb36gRZN{[Xl?	M{DNVlUxKM7:TR?=	M{XFNVQ5KGh?	MVTEUXNQ	MmfmeZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhUEyDIHPsZZN{KEl?	NVfKT4l1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQxOjNpPkK0NlQ1ODJ\|PD;hQi=>
TE5	MXvGeY5kfGmxbjDBd5NigQ>?	NXvxN4h3PTBizszN	M4CzVVQ5KGh?	NVjuSYNDTE2VTx?=	Mn;VeZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhUEyDIHPsZZN{KEl?	NEjveYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0OFAzOyd-MkSyOFQxOjN:L3G+
TE1	NWrncnhGTnWwY4Tpc44hSXO\|YYm=	M4XsVlUxKM7:TR?=	MX60PEBp	MYTEUXNQ	NF\RVI52eHKnZ4XsZZRmeyC2aHWg[ZhxemW\|c3nvckBw\iCKTFGgZ4xie3NiSR?=	M{T6SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkS0NFI{Lz5{NEK0OFAzOzxxYU6=
TE3	Mni5SpVv[3Srb36gRZN{[Xl?	NYnVRZc4PTBizszN	MmPwOFghcA>?	MXTEUXNQ	M{\IZ5VxemWpdXzheIV{KHSqZTDlfJBz\XO\|aX;uJI9nKEiOQTDjcIF{eyCL	NYnQSZlHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQxOjNpPkK0NlQ1ODJ\|PD;hQi=>
KYSE30	MUjGeY5kfGmxbjDBd5NigQ>?	MUSyNE82OC9zMECg{txO	NIToblM1QCCq	NIj6NG5FVVOR	NVLWSZM6cW6qaXLpeJMheC2HcnugZY5lKHexcoTtZY5vcW5iZH;3cpJm\3WuYYTl[EBxNUGtdDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NVP2WIR3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQxOjNpPkK0NlQ1ODJ\|PD;hQi=>
TE1	MYLGeY5kfGmxbjDBd5NigQ>?	M4jjTlIxNzVyL{GwNEDPxE1?	MmD2OFghcA>?	Mn\3SG1UVw>?	MWLpcohq[mm2czDwMWVzcyCjbnSge49zfG2jbn7pckBld3ewcnXneYxifGWmIICtRYt1KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M1\JdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkS0NFI{Lz5{NEK0OFAzOzxxYU6=
TE4	MVfGeY5kfGmxbjDBd5NigQ>?	NV:1eZZvOjBxNUCvNVAxKM7:TR?=	NWLBR5pwPDhiaB?=	M4LIPWROW09?	Ml;GbY5pcWKrdIOgdE1GemtiYX7kJJdwenSvYX7ubY4h\G:5boLl[5Vt[XSnZDDwMWFsfCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	Mo[5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NESwNlMoRjJ2MkS0NFI{RC:jPh?=
HT29	MXrGeY5kfGmxbjDBd5NigQ>?	M3rjeVExKM7:TR?=	NXvxOHh1OiCq		NEP2bIJqdmirYnn0d{Bw\iCMQVuyMEBGWktzL{KgZY5lKFOWQWSzJJBpd3OyaH;yfYxifGmxbh?=	MoC4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NkWyPVMoRjJ2Mk[1Nlk{RC:jPh?=
HepG2	MVnBdI9xfG:\|aYOgRZN{[Xl?	NXr1fI9sOjBizszN	NWW1WW5QOjRiaB?=		MWHpcohq[mm2czDFVmsyNzJicHjvd5Bpd3K7bHH0bY9vKGGwZDDlcohidmOnczDWRlEucW6mdXPl[EBieG:ydH;zbZM>	NFnhPJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0O\|kxQSd-MkSyOFc6ODl:L3G+
HepG2	M{DBOWZ2dmO2aX;uJGF{e2G7	MlS5NlAh\|ryP	NILxeoIzKGh?		MX7lcohidmOnczDWRlEucW6mdXPl[EBHV1iRM3GgeJJidnOlcnnweIlwdmGuIHHjeIl3cXS7	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2N{mwPUc,OjR{NEe5NFk9N2F-
MC-3	MXXBdI9xfG:\|aYOgRZN{[Xl?	NXPFdXlxOTBizszN	MnTrNlQhcA>?		M3PNO5BwfGWwdHnheIVlKE2HU1OtbY5lfWOnZDDhdI9xfG:\|aYOgbY4hKGOnbHzz	NV7pVFhRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyO\|A2OjNpPkK0NlcxPTJ\|PD;hQi=>
Raji	M3jpTmZ2dmO2aX;uJGF{e2G7	M1nqUlExKM7:TR?=	MoX1NUBp		M3[2PIJtd2OtczDod2JCTkZiaX7keYNm\CCHcnuxM\|IheGixc4Doc5J6dGG2aX;u	MnzrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{Nkm2N\|AoRjJ2Mk[5OlMxRC:jPh?=
Raji	NUXIWWpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrRNZl6OTBizszN	M3LLNFEhcA>?		M1rTd4lvcGmkaYTzJJRp\SCkYYPhcEBweiCqc1LBSmYue3SrbYXsZZRm\CClZXzsJJBzd2yrZnXyZZRqd25iYX7kJJZq[WKrbHn0fS=>	MoXZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{Nkm2N\|AoRjJ2Mk[5OlMxRC:jPh?=
A549	NVT0b3AyTnWwY4Tpc44hSXO\|YYm=	MlLiN\|Ah\|ryP	NED4[GMxNjViaB?=	Mk\ySG1UVw>?	MUjpcohq[mm2czD0bJJwdWKrbj3pcoR2[2WmIFOvSWJR\|rJiVHjyNlM2yqCyaH;zdIhwenmuYYTpc44>	M33rNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mke3Olk3Lz5{NEK3O\|Y6PjxxYU6=
HCSMCs	NXPGfVVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY[xNEDPxE1?	MVSyOEBp		MWXicI9kc3NiRlHCVFQucW6mdXPl[EBJS0GVTVOgdJJwdGmoZYLheIlwdg>?	M1vK[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{GyN\|gyLz5{NEOxNlM5OTxxYU6=
PANC-1	NYPHSZNVTnWwY4Tpc44hSXO\|YYm=	NXPTPXFHOjBizszN	MkT5OFghcA>?		MVXpcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjFOmFZFKGmwIILld5BwdnOnIITvJJRp\SCSUFHS{tTDqGGpb37pd5TDqA>?	NGjERXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK5OFE{Oyd-MkSyPVQyOzN:L3G+
A549	NFqzeGZHfW6ldHnvckBCe3OjeR?=	NFO0dYM{OCEQvF2=	Mli3NE42KGh?	MojXSG1UVw>?	MYrpcohq[mm2czD0bIUhfGi{b33ibY4ucW6mdXPl[EBKVC16L1PYR2w5NUy3YzDhZ5Rqfmm2eR?=	Mmn0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{N{e2PVYoRjJ2Mke3Olk3RC:jPh?=
SW480	MXvGeY5kfGmxbjDBd5NigQ>?	NX71PXU2OTBizszN	MnjWNlAhcA>?	M{nLWGROW09?	NVf3dlY5e3WycILld5NmeyC2aHWgR3JVKGGldHn2bZR6	Mnu1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|MkSzOlYoRjJ2M{K0N\|Y3RC:jPh?=
HEK 293	NFG2SoVHfW6ldHnvckBCe3OjeR?=	MoPUNVAh\|ryP	MoXxOUBp	MkLqSG1UVw>?	M2mwT4lvcGmkaYTzJHdvfC2rbnT1Z4VlKM7{LXPheIVvcW5xVFPGOEBi[3Srdnn0fUBidmRiboXjcIVieiEQsj3jZZRmdmmwIHHjZ5VufWyjdHnvci=>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN{NEO2Okc,OjR\|MkSzOlY9N2F-
HEK 293	Ml7pSpVv[3Srb36gRZN{[Xl?	NYrkO5FDOTBizszN	MXm1JIg>	NWHQSXA4TE2VTx?=	NGrnV4V{fXCycnXzd4V{KHSqZTDDVnQh[WO2aY\peJk>	M1LvflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{K0N\|Y3Lz5{NEOyOFM3PjxxYU6=
HL-60	MWTGeY5kfGmxbjDBd5NigQ>?	MUixNE8zOCEQvF2=	NFXYfHIyKGh?		MXfpcohq[mm2czD0bIXDqE5wIHPobY5mdnOrc3X4eJJi[3UEoHnu[JVk\WRiZHnm[oVz\W62aXH0bY9vKGmwdH:g[5JidnWub3P5eIV{	NVvDfIJ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOVcxOjBpPkK0N\|U4ODJyPD;hQi=>
HL-60	NYfWcYRkTnWwY4Tpc44hSXO\|YYm=	NEPINGczKML3TR?=	M2f3ZlE3KGh?	NXjiSGlqTE2VTx?=	MVnpcohq[mm2czD0bIUh[XO\|b3PpZZRqd25ib3[gdHM3OjFiUnHmMVEh[W6mIF7GRXRkOyxiYX7kJJRp\SCUQT3pcoR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDueYNt\WG{IF7GRXRkOw>?	MkjFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|M{CwOlgoRjJ2M{OwNFY5RC:jPh?=
HeLa	NYO3R5k5TnWwY4Tpc44hSXO\|YYm=	NVnqTZR1PTBizszN	MkjRNE42KGh?		MWHicI9kc3NiVGLYMVEhdnWlbHXhdkBucWe{YYTpc44h[W6mIGTYUmlRKGSxd36tdoVofWyjdHnvci=>	NIr6TlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO3OlgzPyd-MkSzO\|Y5Ojd:L3G+
HUVECs	M3LG[GZ2dmO2aX;uJGF{e2G7	M1q2NVExyqEQvF2=	M37JZlEhcA>?		NV3qW\|JVcW6qaXLpeJMhfGinIFjEUEBz\WS3Y3XkJGNQYC1{IHX4dJJme3Orb36gZY5lKFCJST2yJJJmdGWjc3W=	NY\JO3o1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPFUyODlpPkK0N\|g2OTB7PD;hQi=>
MCF-7	NHHMeW5HfW6ldHnvckBCe3OjeR?=	M1OyVFExyqEQvF2=	NFr2NpoyOC9\|MDDtbY4>		MULy[YR2[2W\|IITo[UBWXFBvZHXw[Y5l\W62IFXST{BxcG:\|cHjvdplt[XSrb36=	NHT5U3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO5NFgyQSd-MkSzPVA5OTl:L3G+
HGC-27	MoK0RZBweHSxc3nzJGF{e2G7	M4PlfFEhyrWP	MV2xJIg>		NUTTUmh1e3WycILld5NmeyCUQVSwNFEheGy3czDNT{0zOjB4LXnu[JVk\WRiY3XscEB3cWGkaXzpeJkhdG:\|cx?=	NEP2Ooc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESxOlM1QSd-MkS0NVY{PDl:L3G+
PC3	M3LTfmFxd3C2b4Ppd{BCe3OjeR?=	MVq1NEDPxE1?	NHWye4IxNjViaB?=		MXnpcohq[mm2czDNTHkuPDR7LXnu[JVk\WRiYYDvdJRwe2m\|wrC=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{NEi4PUc,OjR2MkS4PFk9N2F-
HPAEpiCs	M{nBdWZ2dmO2aX;uJGF{e2G7	MYqzNEDPxE1?	NETu[ZIyKGh?		M4KzcYlvcGmkaYTzJHRPTi4QsTDzeIlufWyjdHXkJJA1Oi:yNESgUWFRUyCyaH;zdIhwenmuYYTpc44>	M2HycFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NESxPFcxLz5{NES0NVg4ODxxYU6=
BeWo	MmLLSpVv[3Srb36gRZN{[Xl?	Ml7NNVDDqM7:TR?=	NHTwR\|gzKGh?		NHLxdJlqdmirYnn0d{BGWktzL{K=	NHz1[pQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESzN\|g1Pid-MkS0N\|M5PDZ:L3G+
A498	MYHBdI9xfG:\|aYOgRZN{[Xl?	MmTpOVDDqM7:TR?=	M3;PdVI1KGh?		NUezeWgxeG:2ZX70bYF1\XQEoITo[UBxem9vYYDvdJRwfGmlIHXm[oVkfHNib3[gUmM>	M1HSRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUC4OFc3Lz5{NEWwPFQ4PjxxYU6=
NHBE	MWTGeY5kfGmxbjDBd5NigQ>?	MVGyM\|IxKM7:TR?=	NWnPcWMyOiCq		MU\heJRmdnWjdHXzJGlNNTN\|IIP0bY12dGG2ZXSgR3hEVDhxSVytPEB{\WO{ZYTpc44>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5OUWyOkc,OjR2N{m1NlY9N2F-
A375	NVnmVlk3S2WubDDJcpZie2mxbjDBd5NigQ>?	NUfOZZJWOTEkgKOyNEDDvU1?	NXy0OG02OjRiaB?=		NFuySJpz\WS3Y3XzJI1mdGGwb33hJINmdGxiaX72ZZNqd25?	NYD3NGh[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0OlYxOzZpPkK0OFY3ODN4PD;hQi=>
HBMEC	MXHGeY5kfGmxbjDBd5NigQ>?	MX6xNEDPxE1?	NWDyb5VUOSCq		NY\qcpE3[myxY3vzJHZGT0ZvaX7keYNm\CCHcHjBNkBmgHC{ZYPzbY9v	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR3OEm4Nkc,OjR2NUi5PFI9N2F-
HCT-15	MX\GeY5kfGmxbjDBd5NigQ>?		NGr4bZYyKGh?		MYrheJRmdnWjdHXzJHBITTJvaX7keYNm\CCyaH;zdIhwenmuYYTpc44hd2ZiRYLrxsA>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR\|MUSyOUc,OjV2M{G0NlU9N2F-
HCT-15	M2H5W2Fxd3C2b4Ppd{BCe3OjeR?=		MVGxJIg>		Mmj1ZYJwdGm\|aHXzJJRp\SCycn;0[YN1cX[nIHXm[oVkfHNib3[gVGdGOsLiYXfhbY5{fCCldYLjeY1qdi2rbnT1Z4VlKGGyb4D0c5Nqew>?	NFP1VGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSzNVQzPSd-MkW0N\|E1OjV:L3G+
786-O	NWDCb3pMSXCxcITvd4l{KEG\|c3H5	M4qzb\|UxyqEQvF2=	NYfBTYhlOjRiaB?=		Mn21dI91\W62aXH0[ZPDqHSqZTDwdo8u[XCxcITveIlkKGWoZnXjeJMhd2ZiTlO=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDVyOES3Okc,OjR3MEi0O\|Y9N2F-
HepG2	Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDTbpIzOCEQvF2=	NIPKeHEzPCCq		NHTiboh{fXCycnXzd4V{KFSJRj5OtlEucW6mdXPl[EBk\WyuIIDyc4xq\mW{YYTpc44h[W6mIHnueoF{cW:w	NVi1c\|lkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OlA1QDhpPkK1OVYxPDh6PD;hQi=>
SW480	M1S4OmZ2dmO2aX;uJGF{e2G7	MUOyNOKh\|ryP	M4f2dVHDqGh?		NFjtV\|hz\WS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGFVTjNicILveIVqdg>?	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR2N{ixOkc,OjV2NEe4NVY9N2F-
MDA-MB-231	MoPxSpVv[3Srb36gRZN{[Xl?	MofKNlUh\|ryP	MVKyMVMhcA>?		NHP5eFJl\WO{ZXHz[ZMheC2HUluxM\|Ih[W6mIGOxNFBCPCCneIDy[ZN{cW:w	M4jXZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUW1PFc2Lz5{NUW1OVg4PTxxYU6=
HepG2	NIDvelRHfW6ldHnvckBCe3OjeR?=	MV6xNEDPxE1?	NWS4OY1JPSCq		M3K1foJtd2OtczDwbI9{eGixconsZZRm\CCPQWDLd{BqdmS3Y3XkJIJ6KGW6b3flco92eyCWR1[t{tIy	NYXzTItRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OlA1QDhpPkK1OVYxPDh6PD;hQi=>
MCF-7	MY\GeY5kfGmxbjDBd5NigQ>?	M1m4TVExKM7:TR?=	MYqxJIg>		M1fqXolvcGmkaYTzJGlNNTF6LXXubIFv[2WmIHPlcIwhdWmpcnH0bY9v	M130TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{K3NFEyLz5{NUeyO\|AyOTxxYU6=
H1355	NUXUSG84TnWwY4Tpc44hSXO\|YYm=	MWeyOUDPxE1?	M2TZTVEhcA>?		M{ThfoJtfW62czD0bIUhSlujXWCtbY5lfWOnZDDpcoNz\WG\|ZTDpckBxcG:\|cHjvMWNpczFiYX7kJJBpd3OyaH:tSXJMKGW6cILld5Nqd25?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4OUG4NUc,OjV5NkmxPFE9N2F-
PC12	NHu0TFRHfW6ldHnvckBie3OjeR?=				NGfRd\|dKdmirYnn0bY9vKG:oIH7ldpZmKGe{b4f0bEBn[WO2b4KtcYVlcWG2ZXSgUWFRKGurbnHz[UBi[3Srdnn0fUBqdiCqdX3hckBRSzF{IHPlcIx{NCCLQ{WwJF0hOiEQvF2u	NInCdFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEC3O\|M3Oyd-MUiwO\|c{PjN:L3G+
HT-29	NELpXYZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MX:1JIRigXN?		MYXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWLUK5JINmdGy\|IHHmeIVzKDViZHH5d{BjgSCZU2SxJIF{e2G7LDDJR\|UxKD1iNDFOwG0v	NVvUXIU5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwO\|g{OTZpPkK1NFc5OzF4PD;hQi=>
IEC6	M4jhTWZ2dmO2aX;uJIF{e2G7		NWn5cWJzPSCvaX7z		NH;ub3RKdmirYnn0bY9vKG:oIF3FT\|EwOiCrbjDyZZQhUUWFNjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hTVKNMT:yJIxwd3BicHjvd5Bpd3K7bHH0bY9vKGSxc3XkJFMxKG2rboOgZoVnd3KnIITvJJN1cW23bHH0bY9vKHerdHigNVAmKHOncoXtJIZweiB3IH3pcpMh[nliaX3teY5w[myxdITpcochdWW2aH;kMEBKSzVyIE2gOE4zKM7:TT6=	MojnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyN{izNVYoRjJ3MEe4N\|E3RC:jPh?=
NG 108-15	NF;IdlBHfW6ldHnvckBie3OjeR?=				Mk\VR49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDhZo9tcXOqIF3BVGsh[WO2aY\peJkhcW5ibX;1d4UhdmW3cn;icIF{fG:vYTDhcoQhemG2IHfsbY9u[SCqeXLybYQhVkdiMUC4MVE2KGOnbHzzMEBC[3Srdnn0fUA:KDFyIN88UU4>	Mk\VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV3M{ezOVQoRjF3NUO3N\|U1RC:jPh?=
PC12	Mk\qSpVv[3Srb36gZZN{[Xl?	MkjENVAhfU1?	MkjhOUBpenN?		NIjDRmpC[3SrdnH0bY9vKG:oIF7y[lIwSVKHIHnuJJJifCCSQ{GyJINmdGy\|IHHzd4V{e2WmIHHzJGhQNTFicILveIVqdiCrbnT1Z5Rqd25iYYSgNVAhfU1iYX\0[ZIhPSCqcoOgdJJmfHKnYYTl[EB4cXSqIFrOT{BqdmirYnn0c5IhW1B4MECxNlUh\m:{IEGgbJIh[mWob4LlJINwdXCxdX7kJIFl\Gm2aX;uJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	Mk\hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF\|NEW2PFUoRjJzM{S1Olg2RC:jPh?=
PC12	MlfpSpVv[3Srb36gZZN{[Xl?	M{TwcFExKHWP	NFzoN2g2KGi{cx?=		MofkRYN1cX[jdHnvckBw\iCQcn[yM2FTTSCrbjDyZZQhWENzMjDj[YxteyCjc4Pld5Nm\CCjczDIU{0yKHC{b4TlbY4hcW6mdXP0bY9vKGG2IEGwJJVOKGGodHXyJFUhcHK\|IIDy[ZRz\WG2ZXSge4l1cCCPRVuyJIlvcGmkaYTvdkBWODF{NjDmc5IhOSCqcjDi[YZwemViY3;tdI92dmRiYXTkbZRqd25iYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	M3f6b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{S1Olg2Lz5{MUO0OVY5PTxxYU6=
PC12	NYP0d4E1TnWwY4Tpc44h[XO\|YYm=	NIHL[VQyOCC3TR?=	M3rxR\|UhcHK\|		NG\US3lC[3SrdnH0bY9vKG:oIF7y[lIwSVKHIHnuJJJifCCSQ{GyJINmdGy\|IHHzd4V{e2WmIHHzJGhQNTFicILveIVqdiCrbnT1Z5Rqd25iYYSgNVAhfU1iYX\0[ZIhPSCqcoOgdJJmfHKnYYTl[EB4cXSqIF3FT\|EhcW6qaXLpeI9zKFCGOUiwOVkh\m:{IEGgbJIh[mWob4LlJINwdXCxdX7kJIFl\Gm2aX;uJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN2NU[4OUc,OjF\|NEW2PFU9N2F-
HeLa	MVvGeY5kfGmxbjDhd5NigQ>?	NXH2U4xMOjBidV2=	NFyz[o0{KGi{cx?=		NEjDc4RKdmirYnn0bY9vKG:oIFXST\|EwOiCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hUGWOYTDj[YxteyCjdDCyNEB2VSCjZoTldkA{KGi{czDifUBY\XO2ZYLuJIJtd3S2aX7nJIFv[Wy7c3nz	NUfNVI1kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1O\|A3OTVpPkKzOVcxPjF3PD;hQi=>
RD	Moj5dWhVWyCjc4PhfS=>				M1rCbJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>?	M1PJeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	MlzndWhVWyCjc4PhfS=>				Ml\KdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?=	M2T2[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	MVzxTHRUKGG\|c3H5				NVjOW\|dueUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWkRiY3XscJM>	MnvBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	NILwdo1yUFSVIHHzd4F6				MUDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	M37pRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
TC32	MkjKdWhVWyCjc4PhfS=>				NXTzWYp4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXEN\|MjDj[Yxtew>?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
MDA-MB-231	MonhSpVv[3Srb36gZZN{[Xl?	MnfCOVAhfU1?			NFXPb5RFd3ewcnXneYxifGmxbjDv[kBOVVB{IHnuJIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYYSgOVAhfU1iYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	NX;YW3NERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5NlYzOjZpPkKyPVI3OjJ4PD;hQi=>
MDA-MB-231	Mm\TSpVv[3Srb36gZZN{[Xl?	NV;wPJBiPTBidV2=			MV;Ec5dvemWpdXzheIlwdiCxZjDNUXA6KGmwIHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XRiNUCgeW0h[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl{NkKyOkc,OjJ7Mk[yNlY9N2F-

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot

c-Jun / α-tubulin / p-ERK / ERK / p-AKT / AKT ; p-JNK / JNK / Cyclin D1 ; p-HER2 / HER2 ; MMP9 / XIAP / VEGF

17482134 24244023 29695559

In vivo

Treatment of mice 30 minutes before focal cerebral ischemia with PD98059 protects against damage, resulting in a decrease in infarct volume. ^[5] Pretreated with PD98059 (10 mg/kg per i.v. injection) 30 minutes before and then together with hourly cerulein injections for 3 hours significantly ameliorates cerulein-induced acute pancreatitis ipancreatitis on the basis of pancreatic wet weight and histology. ^[6] Administration of PD98059 (10 mg/kg) in mice 1 hour after carrageenan causes a reduction in all the parameters of inflammation measured. ^[7]

Protocol (from reference)

Kinase Assay: ^[1]	In vitro MEK-inhibitory activity: Incorporation of ³²P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50 μL of 50 mM Tris, pH 7.4/10 mM MgCl₂/2 mM EGTA/10 μM [γ-³²P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE.
Cell Research: ^[1]	Cell lines: K-Balb, KNRK, v-raf-3Y1, SRA/3Y1, EGFR/3T3, and K562 Concentrations: Dissolved in DMSO, final concentrations ~100 μM Incubation Time: 3 dyas, or 7-10 days Method: For monolayer growth, cells are plated into multi-well plates at 10,000-20,000/mL. Forty-eight hours later, various concentrations of PD98059 are added to the cell growth medium and incubation is continued for an additional 3 days. Cells are then removed from the wells by incubation with trypsin and enumerated with a Coulter Counter. For growth in soft agar, cells are seeded into 35-mm dishes at 5,000-10,000 cells per dish with growth medium containing 0.3% agar and desired concentrations of PD98059. After 7-10 days of growth, visible colonies are manually enumerated with the aid of a dissecting microscope.
Animal Research: ^[7]	Animal Models: Male Sprague–Dawley rats with acute pancreatitis Dosages: 10 mg/kg Administration: Injection i.v.

References

+ Expand

Solubility (25°C)

In vitro	DMSO	14 mg/mL warmed (52.37 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order (Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing. Click to purchase: PEG300 Tween 80	1mg/mL

Chemical Information

Molecular Weight	267.28
Formula	C₁₆H₁₃NO₃
CAS No.	167869-21-8
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	COC1=CC=CC(=C1N)C2=CC(=O)C3=CC=CC=C3O2

Download PD98059 SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
How to formulate this inhibitor for i.p. injection?

Answer:
You can prepare the stock by the vehicle 30% PEG400/0.5% Tween80/5% Propylene glycol, 0.5% CMC.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):